In 2010, RNAi Moves into the Mainstream, microRNAs Continue to Garner Interest

Despite advances, there remains much work to be done on the basic biology side of things if RNAi is ever to achieve its promise as a therapeutic modality, industry watchers said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.